Inflammatory Bowel Disease

IBD therapeutics have entered a multi-mechanism era, with selective IL-23 inhibitors (risankizumab, mirikizumab), the S1P receptor modulator etrasimod, and the JAK1-selective upadacitinib joining established anti-TNFs and vedolizumab. STRIDE-II treat-to-target endpoints — clinical remission, biomarker normalization, and endoscopic healing — are reshaping monitoring, with intestinal ultrasound and fecal calprotectin replacing repeat colonoscopy in many programs. Sessions will examine head-to-head positioning (SEQUENCE, VEGA), perianal Crohn’s, pouchitis after IPAA, and the operationalization of therapeutic drug monitoring.